These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 28720429)

  • 1. Stable isotope-based flux studies in nonalcoholic fatty liver disease.
    McCullough A; Previs S; Kasumov T
    Pharmacol Ther; 2018 Jan; 181():22-33. PubMed ID: 28720429
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Micronutrient Antioxidants and Nonalcoholic Fatty Liver Disease.
    Chen G; Ni Y; Nagata N; Xu L; Ota T
    Int J Mol Sci; 2016 Aug; 17(9):. PubMed ID: 27563875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mitochondria Matter: Systemic Aspects of Nonalcoholic Fatty Liver Disease (NAFLD) and Diagnostic Assessment of Liver Function by Stable Isotope Dynamic Breath Tests.
    Di Ciaula A; Calamita G; Shanmugam H; Khalil M; Bonfrate L; Wang DQ; Baffy G; Portincasa P
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299321
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular Mechanisms of Nonalcoholic Fatty Liver Disease (NAFLD)/Nonalcoholic Steatohepatitis (NASH).
    Ota T
    Adv Exp Med Biol; 2021; 1261():223-229. PubMed ID: 33783745
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic syndrome and nonalcoholic fatty liver disease: Is insulin resistance the link?
    Asrih M; Jornayvaz FR
    Mol Cell Endocrinol; 2015 Dec; 418 Pt 1():55-65. PubMed ID: 25724480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mitochondrial Adaptation in Nonalcoholic Fatty Liver Disease: Novel Mechanisms and Treatment Strategies.
    Sunny NE; Bril F; Cusi K
    Trends Endocrinol Metab; 2017 Apr; 28(4):250-260. PubMed ID: 27986466
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
    Takahashi Y; Sugimoto K; Inui H; Fukusato T
    World J Gastroenterol; 2015 Apr; 21(13):3777-85. PubMed ID: 25852263
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Crosstalk between nonalcoholic fatty liver disease and cardiometabolic syndrome.
    Lim S; Taskinen MR; Borén J
    Obes Rev; 2019 Apr; 20(4):599-611. PubMed ID: 30589487
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
    Takahashi Y; Fukusato T
    World J Gastroenterol; 2014 Nov; 20(42):15539-48. PubMed ID: 25400438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-Alcoholic Fatty Liver Disease.
    Engin A
    Adv Exp Med Biol; 2017; 960():443-467. PubMed ID: 28585211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-alcoholic fatty liver disease and dyslipidemia: An update.
    Katsiki N; Mikhailidis DP; Mantzoros CS
    Metabolism; 2016 Aug; 65(8):1109-23. PubMed ID: 27237577
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting Metabolism, Insulin Resistance, and Diabetes to Treat Nonalcoholic Steatohepatitis.
    Finck BN
    Diabetes; 2018 Dec; 67(12):2485-2493. PubMed ID: 30459251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MicroRNAs in the Pathogenesis of Nonalcoholic Fatty Liver Disease.
    Fang Z; Dou G; Wang L
    Int J Biol Sci; 2021; 17(7):1851-1863. PubMed ID: 33994867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integrating the contributions of mitochondrial oxidative metabolism to lipotoxicity and inflammation in NAFLD pathogenesis.
    Hughey CC; Puchalska P; Crawford PA
    Biochim Biophys Acta Mol Cell Biol Lipids; 2022 Nov; 1867(11):159209. PubMed ID: 35934297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mitochondrial Dysfunction Plays Central Role in Nonalcoholic Fatty Liver Disease.
    Ramanathan R; Ali AH; Ibdah JA
    Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35806284
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Utilization of animal models to investigate nonalcoholic steatohepatitis-associated hepatocellular carcinoma.
    Wu J
    Oncotarget; 2016 Jul; 7(27):42762-42776. PubMed ID: 27072576
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integrative transcriptomic analysis of NAFLD animal model reveals dysregulated genes and pathways in metabolism.
    Yang W; He Y; Liu S; Gan L; Zhang Z; Wang J; Liang J; Dong Y; Wang Q; Hou Z; Yang L
    Gene; 2016 Dec; 595(1):99-108. PubMed ID: 27697615
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of fibroblast growth factor 21 in the pathogenesis of non-alcoholic fatty liver disease and implications for therapy.
    Liu J; Xu Y; Hu Y; Wang G
    Metabolism; 2015 Mar; 64(3):380-90. PubMed ID: 25516477
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent Insights into the Pathogenesis of Nonalcoholic Fatty Liver Disease.
    Arab JP; Arrese M; Trauner M
    Annu Rev Pathol; 2018 Jan; 13():321-350. PubMed ID: 29414249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between Vitamin D Levels and Nonalcoholic Fatty Liver Disease: Potential Confounding Variables.
    Pacifico L; Osborn JF; Bonci E; Pierimarchi P; Chiesa C
    Mini Rev Med Chem; 2019; 19(4):310-332. PubMed ID: 30360708
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.